Elanco proves to be investors' best friend

摘要

ELANCO ANIMAL HEALTH, Eli Lilly's animal health unit, exploded onto public markets, achieving above-target pricing on its spinoff IPO and surging 50% on debut. The move immediately validated Lilly's decision to carve out the unit now valued at US$12.2bn.